SXTP vs. ARAV, ARDS, AGRX, ONCO, RNAZ, NBY, CWBR, REVB, SNOA, and BCEL
Should you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Aravive (ARAV), Aridis Pharmaceuticals (ARDS), Agile Therapeutics (AGRX), Onconetix (ONCO), TransCode Therapeutics (RNAZ), NovaBay Pharmaceuticals (NBY), CohBar (CWBR), Revelation Biosciences (REVB), Sonoma Pharmaceuticals (SNOA), and Atreca (BCEL). These companies are all part of the "pharmaceutical preparations" industry.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Aravive (NASDAQ:ARAV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking.
Aravive received 103 more outperform votes than 60 Degrees Pharmaceuticals when rated by MarketBeat users. Likewise, 62.28% of users gave Aravive an outperform vote while only 33.33% of users gave 60 Degrees Pharmaceuticals an outperform vote.
In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Aravive. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Aravive. Aravive's average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.50 indicating that Aravive is being referred to more favorably in the news media.
8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
60 Degrees Pharmaceuticals has a net margin of 0.00% compared to Aravive's net margin of -569.65%.
60 Degrees Pharmaceuticals currently has a consensus target price of $2.40, suggesting a potential upside of 910.10%. Aravive has a consensus target price of $13.50, suggesting a potential upside of 33,565.84%. Given Aravive's higher probable upside, analysts clearly believe Aravive is more favorable than 60 Degrees Pharmaceuticals.
60 Degrees Pharmaceuticals has higher earnings, but lower revenue than Aravive.
Summary
60 Degrees Pharmaceuticals and Aravive tied by winning 7 of the 14 factors compared between the two stocks.
Get 60 Degrees Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
60 Degrees Pharmaceuticals Competitors List
Related Companies and Tools
